Menu

Salk Gender-Discrimination Lawsuit to Go to Trial

A judge throws out several of researcher Beverly Emerson’s claims, but the case proceeds.

Sep 4, 2018
Shawna Williams

ABOVE: FLICKR, JASON TAELLIOUS

Molecular biologist Beverly Emerson’s case against the Salk Institute will go to trial this December, after a judge last week (August 30) threw out three of her claims but let one stand. Emerson, now a professor emerita at Salk, says she was for decades denied professional opportunities available to male faculty members at the institute.

“We are pleased with the court’s order and look forward to defending against the remaining claims,” Summer Wynn, an attorney representing the Salk, tells The San Diego Union-Tribune. Alreen Haeggquist, Emerson’s attorney, tells the publication that the decision was “a victory for Dr. Emerson, and a tremendous step forward for women scientists at Salk, as the court ruled that there is ample evidence to proceed to trial, and that the institute will be held accountable for decades of gender discrimination.”

See “Salk Faces Gender Discrimination Lawsuits

More than a year ago, Emerson joined two other Salk scientists, Vicki Lundblad and Katherine Jones, in suing the institute; Lundblad and Jones later settled. The trio, who together represented three-quarters of the institute’s female full professors, claimed that their labs received less funding than those of their colleagues and that their promotion rates were slower.

See “Salk Institute Settles Two Gender Discrimination Suits

In a statement last summer, Salk said Lundblad and Jones had “been treated generously by the institute, including relative to their male peers,” according to the Union-Tribune. “Each scientist’s lucrative compensation package is consistent with well-recognized metrics that have been applied to all Salk faculty in a nondiscriminatory manner.”

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.